Conor Driscoll

Dr. Conor Driscoll

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
BHBenjamin S. Hopkins
Benjamin S. Hopkins
AMAditya Mazmudar
Aditya Mazmudar
CDConor Driscoll
Conor Driscoll
MSMark Svet
Mark Svet
JGJack Goergen
Jack Goergen
NDNader S Dahdaleh
Nader S Dahdaleh

24 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CDConor Driscoll
Conor Driscoll
JRJordan M. Rich
Jordan M. Rich
DIDylan Isaacson
Dylan Isaacson
JNJoseph Nicolas
Joseph Nicolas
YJYu Jiang
Yu Jiang
SKShilajit D. Kundu
Shilajit D. Kundu
Over the last two decades, tumor necrosis factor-alpha inhibitors (TNF-Is) have become standard therapies for chronic inflammatory disorders, with an ongoing expansion of indications and off-label applications

1 December 2020 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
JYJonathan T. Yamaguchi
Jonathan T. Yamaguchi
HWHannah K. Weiss
Hannah K. Weiss
RGRoxanna M. Garcia
Roxanna M. Garcia
CDConor Driscoll
Conor Driscoll
ESEli Stein
Eli Stein
NDNader S. Dahdaleh
Nader S. Dahdaleh

1 September 2020 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
MCMichael B. Cloney
Michael B. Cloney
CDConor Driscoll
Conor Driscoll
JYJonathan T. Yamaguchi
Jonathan T. Yamaguchi
BHBenjamin Hopkins
Benjamin Hopkins
NDNader S. Dahdaleh
Nader S. Dahdaleh

26 November 2025 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
CDConor Driscoll
Conor Driscoll
NHNicole Handa
Nicole Handa
MHMitchell M. Huang
Mitchell M. Huang
AMAdam B. Murphy
Adam B. Murphy
JHJim C. Hu
Jim C. Hu
ESEdward M. Schaeffer
Edward M. Schaeffer
Purpose: Non-White patients are poorly represented in prostate cancer trials. MRI PI-RADS scoring was developed in primarily White populations, but prostate cancer differs in non-White men. We aimed to explore differences in PI-RADS calibration for Asian and Black men. Materials and methods: This is a secondary analysis of PREVENT, a multi-institutional study of infection rates for transrectal vs. transperineal biopsy. We compared cancer detection for self-identifying Asian and Black men. We compared detection rates on a per-person basis, stratified by index PI-RADS lesion, to White men, using Fisher’s exact and logistic regression. Results: Of 665/752 trial patients with PI-RADS 3-5 lesions, 88 (13%) were Black and 36 (6%) were Asian. Black men were younger at diagnosis with increased rates of overall (70% vs. 43%%, P = 0.004) and clinically significant prostate cancer (60% vs. 27%, P = 0.003) and Asian men had decreased rates of overall (0% vs. 47%, P = 0.004) and clinically significant prostate cancer (0% vs. 27%, P = 0.003) in PI-RADS 3 lesions compared to White men. On multivariable regression, Black men with PI-RADS 3/4 lesions had higher odds of overall (OR 1.17, P = 0.009) and clinically significant prostate cancer (OR 1.20, P = 0.004) and Asian men had lower odds of overall (OR 0.79, P = 0.01) but not clinically significant prostate cancer (OR 0.94, P = 0.5). Conclusions: Black men with PI-RADS 3/4 lesions had 20% higher odds of clinically significant prostate cancer than White men while all PI-RADS 3 lesions in Asian men were negative. These findings suggest PI-RADS may require differential interpretation when assessing prostate cancer risk in non-White men. Trial Registration: Registered at ClinicalTrials.gov ( NCT04843566 , https://clinicaltrials.gov/study/NCT04843566 ).

28 October 2025 in Cancer
Verified
Journal Article
Open access
MHMitchell M. Huang
Mitchell M. Huang
CDConor Driscoll
Conor Driscoll
NHNicole Handa
Nicole Handa
BWB. Malik Wahba
B. Malik Wahba
ALAaron A. Laviana
Aaron A. Laviana
ESEdward M. Schaeffer
Edward M. Schaeffer
Background: As antimicrobial resistance increases, safer alternative approaches to prostate biopsy are needed. PREVENT was a multi‐institutional, randomized controlled trial comparing transperineal (TP) biopsy without antibiotic prophylaxis versus transrectal (TR) biopsy with targeted prophylaxis. The authors conducted a secondary cost‐effectiveness analysis of PREVENT. Methods: The authors designed a Markov model with a simulated cohort of 1000 biopsied men. They assessed the short‐term cost‐effectiveness over a 2‐week period, comparing relative costs in US dollars and utility measured in quality‐adjusted life years (QALYs). The strategies they compared were office‐based, magnetic resonance imaging‐guided biopsy using two approaches: (1) TP without antibiotics; or (2) TR with targeted antibiotic prophylaxis. Analysis was from a health care payer perspective using a willingness‐to‐pay (WTP) threshold of $100,000/QALY. Probabilistic sensitivity analysis was performed with 5000 Monte Carlo simulations. Results: Compared to TR, TP was dominant, offering lower cost and higher utility per patient. This finding was robust to sensitivity analyses with TP having >89% probability of cost‐effectiveness regardless of WTP threshold. TP remained dominant when real‐world infection rates were used. TP biopsy needed to prevent >0.5% infections compared to TR to maintain cost‐effectiveness. Per 1000 patients, TP biopsy prevented 16 infections, and the additional cost to prevent a single infection was $3.18/patient. Conclusions: In this model, TP biopsy was more cost‐effective than TR from a health care payer perspective. In the setting of increasing concerns about the risk of infection from traditional TR biopsy, these findings suggest that office‐based TP biopsy is a more cost‐effective population‐level alternative.